Daniel Gaudet, MD, PhD: Contextualizing Plozasiran Data from SHASTA-2, Upcoming MUIR Data

Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.

Related Keywords

Daniel Gaudet ,Eli Lilly ,Boehringer Ingelheim ,American College Of Cardiology ,Novo Nordisk ,Arrowhead Pharmaceuticals ,Astrazeneca ,American College ,Annual Scientific Session ,Arrowhead Pharmaceutical ,New Amsterdam Pharma ,